NASDAQ | TSX: ACB
Canada's
Largest Medical Cannabis Company Continues to Offer Greater Choice
for Patients
EDMONTON, AB, Nov. 26,
2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:
ACB), the Canadian-based leading global medical cannabis company,
announces developments in cannabis science from Aurora's world
class research and genetics facility, Aurora Coast. With a
continued focus on premium, science-driven insights, these latest
innovations demonstrate Aurora's commitment to providing patients
with ongoing access to superior product offerings on
AuroraMedical.com.
"As a company committed to leading the way in terms of cannabis
innovation, we are dedicated to putting patients first by
harnessing the innovative solutions developed by our top
researchers at Aurora Coast, our unique global research facility,"
said Lana Culley, Vice President,
Science & Innovation at Aurora. "We strive to continuously
raise the bar on product superiority and overall user experience so
that we can deliver on our mission of providing patients with
access to the very best medical cannabis."
The latest innovations include:
- Aurora | CBD Varius (1g, 510 Cartridge); a smooth and
refined option for patients.
- MedReleaf (Strains For Heroes) | Esprit De Corps (5g and
15g); a premium sativa (THC: 20-29%, CBD: 0-1%), developed under
the Strains For Heroes initiative by Aurora with direct
feedback from Veteran patients.
- MedReleaf | Sedamen (1g, 510 Cartridge); a
patient-favourite in a higher THC, larger format.
- MedReleaf | Noculus (5g and 15g); an ultra-high potency
indica, boasting THC levels between 25-31% and CBD content from
0-1%.
- WMMC | Seasonal Stash - Frosted Alpine (10g); a limited
grown hybrid strain (THC: 24-30%; CBD: 0-1%).
Aurora's world class research and development facility, Aurora
Coast, located in Comox, Vancouver
Island, is home to some of the most advanced cannabis research and
genetics discovery work worldwide. New cultivars developed at
Aurora Coast are subsequently grown across Aurora's Canadian
cultivation network where the company adheres to the highest
production practices at its EU-GMP and TGA -GMP certified
facilities. Aurora partners with several other licensed producers
who have licenses to grow its cultivars creating more value for
both Aurora and the broader industry.
Aurora's industry-leading portfolio of medical cannabis products
is available online via Aurora's comprehensive medical patient
platform at AuroraMedical.com. Patients can access a wide range of
innovative, high-quality products tailored to meet their needs.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and South
America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis
brands include MedReleaf, CanniMed, Aurora and Whistler Medical
Marijuana Co., as well as international brands, Pedanios, Bidiol,
IndiMed and CraftPlant. Aurora also has a controlling interest in
Bevo Farms Ltd., North America's
leading supplier of propagated agricultural plants. Driven by
science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry
leaders in the medical, wellness and adult recreational markets
wherever they are launched. Learn more
at www.auroramj.com and follow us
on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
Forward Looking Information:
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the Company's recent medical cannabis
product advancements and the Company's continued commitment to
premium, science-driven insights and to providing patients with
ongoing access to superior product on its medical eCommerce
site.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises and
other risks, uncertainties and factors set out under the heading
"Risk Factors" in the Company's annual information from dated
June 20, 2024 (the "AIF") and filed
with Canadian securities regulators available on the Company's
issuer profile on SEDAR+ at www.sedarplus.com and filed with and
available on the SEC's website at www.sec.gov. The Company cautions
that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-announces-medical-product-advancements-from-leading-cannabis-research-facility-302315930.html
SOURCE Aurora Cannabis Inc.